BIOGEN Business Summary

Biogen Inc. (BIIB) is a global biotechnology leader specializing in the discovery and commercialization of therapies for neurological and rare diseases, generating revenue through direct product sales, collaboration royalties, and contract manufacturing. The company’s business is structured around four core segments: Multiple Sclerosis (MS), featuring legacy treatments like Tysabri and the oral therapy Vumerity; Rare Disease, led by the spinal muscular atrophy drug Spinraza and the Friedreich’s ataxia treatment Skyclarys; Biosimilars; and a high-priority "Growth Products" portfolio including the Alzheimer’s therapy Leqembi (partnered with Eisai), the postpartum depression drug Zurzuvae, and the ALS treatment Qalsody. As of February 2026, Biogen is executing a strategic pivot to offset mid-teen percentage revenue erosion in its legacy MS franchise by scaling its anti-amyloid and rare disease assets, supported by a 2025 total revenue of $9.9 billion. Biogen competes directly with Eli Lilly, Novartis, Sanofi, and Amgen, maintaining a dominant market position in the Alzheimer’s space with over 60% of the anti-amyloid therapy market share. Biogen was founded in 1978 by a distinguished scientific team including Nobel laureates Walter Gilbert and Phillip Allen Sharp, alongside Kenneth Murray, Heinz Schaller, and Charles Weissmann. The current executive leadership is headed by President and CEO Christopher A. Viehbacher, a veteran pharmaceutical leader and former CEO of Sanofi who joined in late 2022 to spearhead the company’s commercial revitalization. The C-suite includes Executive VP and CFO Robin Kramer, who manages financial strategy and capital allocation, and Head of Development Priya Singhal, M.D., who oversees the firm’s late-stage pipeline and regulatory milestones. Other key executives include Head of Research Jane Grogan, Ph.D., and Head of Pharmaceutical Operations and Technology Nicole Murphy. The Board of Directors is currently chaired by Caroline Dorsa, with Dr. Maria C. Freire designated as the incoming Chair effective June 2026. The company maintains a robust institutional investor base, with significant holdings by major asset managers including The Vanguard Group, BlackRock, and State Street.